amylin glp 1 dual agonist Amycretin — a novel obesity treatment that targets both GLP-1 and receptors — has shown early success in phase testing and will be advanced into phase 3 testing. http://ms.spr.ly/6185SLoJD Amylin: From Mode of Action

Realworld weightloss effectiveness of glucagonlike peptide1 agonists among patients with type 2 diabetes: A retrospective cohort study

Potential mechanisms of clot formation related to Ozempic (semaglutide) use: Gastrointestinal effects: Known side effects of Ozempic, such as diarrhea and vomiting, can lead to dehydration which raises blood viscosity and clot risk

[22] Levoamphetamine was previously available as Cydril

This diet proved effective, with more than half of the children with epilepsy showing clinical improvement, leading to its adoption as a standard therapy

Studies show it protects against gastric ulcers, inflammatory bowel disease lesions, and NSAID-induced gut damage by enhancing mucosal integrity and blood vessel formation